<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: The importance of bioactive <z:chebi fb="23" ids="18059">lipid</z:chebi> signaling under physiological and pathophysiological conditions is progressively becoming recognized </plain></SENT>
<SENT sid="1" pm="."><plain>The disparate distribution of <z:chebi fb="0" ids="16393">sphingosine</z:chebi> kinase (SphK) isoform activity in <z:mpath ids='MPATH_458'>normal</z:mpath> and ischemic brain, particularly the large excess of SphK2 in cerebral microvascular endothelial cells, suggests potentially unique cell- and region-specific signaling by its product <z:chebi fb="0" ids="37550">sphingosine-1-phosphate</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>The present study sought to test the isoform-specific role of SphK as a trigger of hypoxic preconditioning (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e>)-induced ischemic tolerance </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Temporal changes in microvascular SphK activity and expression were measured after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The SphK inhibitor dimethylsphingosine or <z:chebi fb="0" ids="16393">sphingosine</z:chebi> analog FTY720 was administered to adult male Swiss-Webster ND4 mice before <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Two days later, mice underwent a 60-minute transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> and at 24 hours of reperfusion, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, neurological deficit, and hemispheric <z:hpo ids='HP_0000969'>edema</z:hpo> were measured </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> rapidly increased microvascular SphK2 protein expression (1.7+/-0.2-fold) and activity (2.5+/-0.6-fold), peaking at 2 hours, whereas SphK1 was unchanged </plain></SENT>
<SENT sid="7" pm="."><plain>SphK inhibition during <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> abrogated reductions in <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, neurological deficit, and ipsilateral <z:hpo ids='HP_0000969'>edema</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e>-treated mice </plain></SENT>
<SENT sid="8" pm="."><plain>FTY720 given 48 hours before <z:hpo ids='HP_0001297'>stroke</z:hpo> also promoted ischemic tolerance; when combined with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e>, even greater (and dimethylsphingosine-reversible) protection was noted </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: These findings indicate <z:mp ids='MP_0005039'>hypoxia</z:mp>-sensitive increases in SphK2 activity may serve as a proximal trigger that ultimately leads to <z:chebi fb="0" ids="37550">sphingosine-1-phosphate</z:chebi>-mediated alterations in gene expression that promote the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-tolerant phenotype </plain></SENT>
<SENT sid="10" pm="."><plain>Thus, components of this bioactive <z:chebi fb="23" ids="18059">lipid</z:chebi> signaling pathway may be suitable therapeutic targets for protecting the neurovascular unit in <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>